BIO vs PROF · rev $2.58B vs rev $10.7M
BIO (BIO) versus Profound Medical Corp (PROF) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Profound Medical Corp (PROF) is a medical devices company listed on NASDAQ.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported PROF revenue for 2024-12-31 was $10.7M. Net income was -$27.8M. Revenue was up 48.4% from 2023-12-31 to 2024-12-31. PROF currently screens at market cap $238.7M.
BIO currently screens at market cap $0. PROF currently screens at market cap $238.7M.
Not investment advice. Open the BIO and PROF stock pages for the full models.
Not investment advice.